Navidea enrolls 1st patient in Phase III trial of NAV4694

06/27/2013 | (free registration)

Navidea Biopharmaceuticals said it has signed up the first patient in a Phase III trial that will test the PET imaging agent NAV4694. The study will evaluate the safety and efficacy of the agent in identifying beta amyloid in end-of-life patients with and without dementia. The study, to eventually include 275 individuals, will compare imaging data during life with autopsy findings.

View Full Article in: (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA